New insights into drug development for pediatric solid tumors: What preclinical data justify clinical trials in pediatric cancer?

Expert Review of Anticancer Therapy

Volumn 13, Issue 10, 2013, Pages 1135-1138

  Houghton, Peter J ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

childhood cancer; clinical trials; drug development; pediatrics; solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE;

BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG INDICATION; DRUG INDUSTRY; DRUG RESPONSE; EDITORIAL; EWING SARCOMA; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 84886390075     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.845094     Document Type: Editorial

References (17)

1. Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong? Nat. Rev. Clin. Oncol. 8(4), 189-190 (2011).
2. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9(4), 215-222 (2012).
3. Kolb EA, Gorlick R, Reynolds CP et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr. Blood Cancer. 60(8), 1325-1332(2013).
4. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40(6), 837-844 (2004).
5. Wong H, Choo EF, Alicke B et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 18(14), 3846-3855 (2012).
6. Santana VM, Zamboni WC, Kirstein MN et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin. Cancer Res. 9(2), 633-640 (2003).
7. Leggas M, Stewart CF, Woo MH et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res. 8(9), 3000-3007(2002).
8. Lock RB, Carol H, Maris JM et al. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 60(7), E42-E45 (2013).
9. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 483(7391), 531-533 (2012).
10. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10(9), 712 (2012).
11. Houghton PJ, Morton CL, Tucker C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer. 49(7), 928-940 (2007).
12. Stegmaier K, Wong JS, Ross KN et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007;4(4), e122 (2007).
13. Houghton PJ, Morton CL, Kang M et al. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr. Blood Cancer 55(6), 1224-1226 (2010).
14. DuBois SG, Krailo MD, Lessnick SL et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr. Blood Cancer 52(3), 324-327 (2009).
15. Houghton PJ, Cheshire PJ, Hallman JD et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36(5), 393-403 (1995).
16. Houghton JA, Cook RL, Lutz PJ, Houghton PJ. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat. Rep. 69(1), 91-96 (1985).
17. Winter GE, Rix U, Lissat A et al. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol. Cancer Ther. 10(10), 1846-56 (2011).